Combined ACE inhibitor, angiotensin-receptor-blocker, non-dihydropyridine calcium-channel-blocker, and statin therapy (Remission Clinic) reduced proteinuria and halted progression in non-diabetic nephropathies, but their efficacy in Alport syndrome (AS) nephropathy is unknown.
A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study
ROCCATELLO, Dario;
2015-01-01
Abstract
Combined ACE inhibitor, angiotensin-receptor-blocker, non-dihydropyridine calcium-channel-blocker, and statin therapy (Remission Clinic) reduced proteinuria and halted progression in non-diabetic nephropathies, but their efficacy in Alport syndrome (AS) nephropathy is unknown.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
PMC4451141.pdf
Accesso aperto
Dimensione
166.8 kB
Formato
Adobe PDF
|
166.8 kB | Adobe PDF | Visualizza/Apri |
|
A Multidrug_4aperto.pdf
Open Access dal 02/05/2016
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
535.63 kB
Formato
Adobe PDF
|
535.63 kB | Adobe PDF | Visualizza/Apri |
|
381480.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
350.47 kB
Formato
Adobe PDF
|
350.47 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
